Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
ANI Pharmaceuticals
ANIP
ANI Pharmaceuticals
Pharmaceutical Pricing Pressures Will Erode Margins Amid Tighter Controls
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 8 Analysts
Published
17 Aug 25
Updated
17 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$77.00
17.0% overvalued
intrinsic discount
17 Aug
US$90.12
Loading
1Y
47.3%
7D
2.0%
Author's Valuation
US$77.0
17.0% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$77.0
17.0% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-69m
936m
2014
2017
2020
2023
2025
2026
2028
Revenue US$936.3m
Earnings US$97.2m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
7.17%
Pharma revenue growth rate
0.55%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$97.21m
Earnings '28
x
20.25x
PE Ratio '28
=
US$1.97b
Market Cap '28
US$1.97b
Market Cap '28
/
21.91m
No. shares '28
=
US$89.86
Share Price '28
US$89.86
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$73.81
Fair Value '25
